Skip to main content
Commentary: IL-31 inhibitor, e-cigarettes, and upadacitinib in AD, April 2023
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Commentary: IL-31 inhibitor, e-cigarettes, and upadacitinib in AD, April 2023
User login
Username
Password
Reset your password
Concept
Lead
score
Dermatitis
1
0.29
Fatigue
0
0.65
Child
0
0.56
Biologic Therapy
0
0.85
Clinical Research
0
0.31
Patient Safety
0
0.95
Juvenile Rheumatoid Arthritis (JRA)
0
0.55
Interleukin
0
0.65
Atopic Dermatitis
0
1
Adverse Effects
0
0.85
Disease Management
0
0.65
Drug and Treatment Safety
0
0.75
Eczema
0
0.06
Sleep
0
0.06
Specialty
Lead
score
Family Medicine/Primary Care
1
1
Dermatology
0
1
Pediatrics
0
1
Orthopaedics
0
0.49
Allergy & Clinical Immunology
0
0.38
Rheumatology
0
0.18
Edit Tags